Medtronic (MDT) Stock Forecast & Price Target

Medtronic is projected to experience consistent sales growth of 7.2% in FY27, driven by its strong product pipeline and market share in key end-markets such as cardiology and minimally invasive technologies. Their innovative medical devices, including Altaviva and Symplicity Spyral, have shown significant improvement in patient outcomes, leading to a potential increase in market penetration of these products. Additionally, the company has consistently allocated a large portion of cash towards share repurchases, which may further drive EPS growth.

Medtronic is facing a variety of challenges that could impact its revenue growth and earnings, including slower product growth and regulatory approvals, increased competition in key market segments, and macroeconomic challenges that could slow down global GDP growth. Despite the potential for sustained growth in the near term, the analyst also identifies risks to the company's success, such as structural heart/tissue aortic valve replacement softness and gross margins under pressure from product mix. The analyst maintains a negative outlook on Medtronic's stock due to these factors and also highlights macroeconomic volatility and potential challenges with capital allocation as potential areas of concern. The analyst has a price target of $104 for the stock, based on a P/E multiple of 17.0x applied to their adjusted EPS estimate for 2027. However, the analyst notes that the ongoing transformation at Medtronic, including its significant pipeline of products and potential for additional upside, could create meaningful upside for the stock.